Fexofenadine hydrochloride

Drugs of the Future

Volumn 21, Issue 10, 1996, Pages 1017-1021

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE;

ALLERGIC RHINITIS; ALLERGY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; ELECTROCARDIOGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY;

EID: 0029853302     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.10.375536     Document Type: Short Survey

References (23)

1. King, C.-H., Kaminski, M.A. (Merrell Dow Pharm., Inc.). 4-Diphenylmethyl piperidine derivs. and process (or their preparation. WO 9321156.
2. Krauss, R.C., Strom, R.M., Scortichini, C.L., Kruper, W.J., Wolf, R.A., Carr, A.A., Rudisill, D.E., Panzone, G., Hay, D.A., Wu, W.W. (Merrell Dow Pharm., Inc.). Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivs. WO 9500480.
3. Prous, J.R. Treatment of upper respiratory tract disorders. In: The Year's Drug News - Therapeutic Targets, 1995 Edition, Prous Science Publishers, Barcelona, 1995, 141-7.
4. NDA submission for terfenadine carboxylate announced by Hoechst Marion Roussel. Filing by partner marks first NDA submission for drug covered by Sepracor patent. Sepracor Inc. News Release, October 24, 1995.
5. Mealy, N., Ngo, J., Castañer, J. Mizolastine. Drugs Fut 1996, 21 (8): 799-804.
6. Garteiz, D.A., Hook, R.H., Walker, B.J., Okerholm, R.A. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim-Forsch-Drug Res 1982, 32(9a): 1185-90.
7. Hey, J.A., del Prado, M., Sherwood, J., Kreutner, W., Egan, R.W. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneim-Forsch-Drug Res 1996, 46(2): 153-8.
8. Stolz, M., Yu, D., Arumugham, T., Bhargava, V., Weir, S. Evaluation of the effect of food on rate and extent of MDL 16,455A absorption. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8370.
9. Lippert, C., Ling, J., Brown, P., Burmaster, S., Eller, M., Cheng, L., Thompson, R., Weir, S. Mass balance and pharmacokinetics of MDL 16,455A in healthy, male volunteers. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8253.
10. Russell, T., Arumugham, T., Eller, M., Weir, S. A comparison of MDL 16,455A pharmacokinetics by gender. Pharm Res 1995, 12(9, Suppl.): AbSt PPDM 8252.
11. Rao, N., Weilert, D.R., Grace, M.G.A., Eller, M.G., Weir, S.J. Pharmacokinetics of terfenadine-acid-metabolite, MDL 16,455A, in healthy geriatric subjects. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8240.
12. Jurima-Romet, M., Crawford, K., Cyr, T., Inaba, T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azote antifungals. Drug Metab Dispos 1994, 22(6): 849-57.
13. Guthrie, J.R., Parente, E., Jones, D.R., Rosanske, T.W. Solution stability of MDL 16,455A (terfenadine acid metabolite). Pharm Res 1995, 12(9, Suppl.): Abst APQ 1210.
14. Chan, K.Y., George, R.C., Chen, T.-M., Okerholm, R.A. Direct enantiomeric separation of terfenadine and its major acid metabolite by high-performance liquid chromatography, and the lack of stereoselective terfenadine enantiomer biotransformation in man. J Chromatogr Biomed Appl 1991, 571(1-2): 291-7.
15. Chen, T.-M., Chan, K.Y., Coutant, J.E., Okerholm, R.A. Determination of the metabolites of terfenadine in human urine by thermospray liquid chromatography-mass spectrometry. J Pharmaceut Biomed Anal 1991, 9(10-12): 929-33.
16. Day, J.H., Briscoe, M.P., Welsh, A., Smith, J., Mason, J. Onset of action, efficacy and safety of a single dose of 60 mg and 120 mg fexofenadine HCl for ragweed (RW) allergy using controlled antigen exposure in an environmental exposure unit (EEU). J Allergy Clin Immunol 1996, 97(1, Part 3): AbSt 1007.
17. Tinkelman, D., Falljers, C., Bronsky, E., Kaiser, H., Mason, J. Efficacy and safety of fexofenadine HCl in fall seasonal allergic rhinitis. J Allergy Clin Immunol 1996, 97(1, Part 3): Abst 1009.
18. Bernstein, D., Schoenwetter, W., Nathan, R., Storms, W., Mason, J. Fexofenadine: A new nonsedating antihistamine is effective in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996, 97(1, Part 3): Abst 1010.
19. McNutt, B.E. (Marion Merrell Dow Inc.). Treatment of allergic disorders with terfenadine carboxylate. WO 9510278.
20. Young, J.W., Gray, N.M., Woosley, R.L., Chen, Y. (Sepracor Inc./Georgetown University). Terfenadine metabolites and their optically pure isomers for treating allergic disorders. AU 9347986, EP 701443, GB 2284351, US 5375693.
21. New non-sedating antihistamine now available: Allegra™ offers safe, fast, effective relief to seasonal allergy sufferers. Hoechst Marion Roussel News Release, August 20, 1996.
22. Sepracor announces agreement with Andrx on terfenadine carboxylate: Company to develop new form of its nonsedating antihistamine for major markets outside the U.S. Sepracor Inc. News Release, April 22, 1996.
23. Sepracor Inc. Smith Barney Bulletin, February 8, 1995.